Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 4, 1999, Pages 266-270

  Metlas, Radmila ^a,b,c   Trajkovic, D ^c,d   Srdic, T ^a,b,d   Veljkovic, V ^a,b   Colombatti, A ^d,e  

^a R and D Institute   (Serbia)

^b Diapharm Ltd   (Serbia)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e UNIVERSITY OF UDINE   (Italy)

Author keywords

Anti V3 antibodies; Autoantibodies; gp 120 V3 loop; HIV

Indexed keywords

AUTOANTIBODY; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; COMPLEMENTARITY DETERMINING REGION; COVALENT BOND; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; NORMAL HUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; SEQUENCE HOMOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033179410     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199908010-00002     Document Type: Article

References (22)

1. Dalgleish AG. Annotation, Autoimmune mechanisms of depletion of CD4 cells in HIV infection. Br J Haematol 1995;91:525-34.
2. Susal C, Kropelin M, Daniel V, Opelz G. Molecular mimicry between HIV-1 and antigen receptor molecules: a clue to the pathogenesis of AIDS. Vox Sang 1993;65:10-17.
3. Cohen IR, Young DB. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991;12:105-10.
4. Coffin JM. Genetic variation in AIDS virus. Cell 1986;46:1-4.
5. Garrity RR, Rimmelzwaan G, Minassian A, et al. Focusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 1997;159:279-89.
6. Veljkovic V, Metlas R. Identification of immunoglobulin recombination elements in human immunodeficiency virus type 1 envelope gene. Immunol Lett 1992;31:11-14.
7. Metlas R, Veljkovic V, Paladini RD, Sandor S. Protein and DNA-sequence homology between the V3 loop of human immunodeficiency virus type 1 envelope protein gp120 and immunoglobulin variable region. Biochem Biophys Res Commun 1992;179:1056-62.
8. Metlas R, Veljkovic V. Does the HIV-1 manipulate immune network via gp120 immunoglobulin-like domain involving V3 loop? Vaccine 1995;13:355-9.
9. Takumi K, De Boer RJ. Self assertion modeled as a network repertoire of multi-determinant antibodies. J Theor Biol 1996;7:55-66.
10. Mouthon L, Nobrega A, Nicolas N, et al. Invariance and restriction towards a limited set of self-antigens characterize neonatal IgM repertoires and prevail in autoreactive repertoires of healthy adults. Proc Natl Acad Sci USA 1995;92:3839-43.
11. Muller S, Wang HT, Kaveri SV, Chattopadhyay, Kohler H. Generation and specificity of monoclonal anti-idiotypic antibodies against human HIV-specific antibodies 1. Cross-reacting idiotypes are expressed in subpopulations of HIV-infected individuals. J Immunol 1991;147:933-41.
12. Wang QL, Wang HT, Blalock E, Muller H, Kohler H. Identification of an idiotypic peptide recognized by autoantibodies in human immunodeficiency virus-1-infected individuals. J Clin Invest 1995;96:775-80.
13. Kion TA, Hoffmann GW. Anti-HIV and anti-anti-HIV antibodies in alloimmune and autoimmune mice. Science 1991;253:1138-40.
14. Lombardi V, Placido R, Scarlatti G, et al. Epitope specificity, antibody dependent cellular cytotoxicity and neutralizing activity of anti-HIV-1 antibodies present in autoimmune MRL/lpr mice. J Infect Dis 1993;167:1267-73.
15. Metlas R, Trajkovic D, Srdic T, Veljkovic N, Colombatti A, Veljkovic V. Human immunodeficiency virus (HIV) V3-loop-peptide reactive antibodies present in normal HIV-negative sera. AIDS Res Hum Retroviruses (in press).
16. Metlas R, Skerl V, Veljkovic V, Colombatti A, Pongor S. Immunoglobulin-like domain of HIV-1 envelope glycoprotein gp120 encodes putative internal image of some common human proteins. Virol Immunol 1994;7:215-19.
17. Metlas R, Skerl V, Pongor S, Colombatti A, Veljkovic V. Reactivity of AIDS patient sera with a peptide derived from HIV type 1 NY5 glycoprotein gp120 V3 loop and consensus sequence of collagens. AIDS Res Hum Retroviruses 1994;10:1425-6.
18. Schreiber M, Petersen H, Wachsmuth C, Muller H, Hufert FT, Schmitz H. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum. J Virol 1994;68:3908-16.
19. Mascola J, Weislow O, Snyder S, et al. Neutralizing antibody activity in sera from human immunodeficiency virus type-1 vaccine recipients from the AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses 1994;10:S55.
20. Kahn JO, Steimer KS, Baezinger J, et al. Clinical, immunological, and virologic observations related to human immunodeficiency virus (HIV) type 1 in a volunteer in an HIV-1 vaccine clinical trial. J Infect Dis 1995;171:1343-7.
21. Kohler H, Muller S, Nara P. Deceptive imprinting in the immune response against HIV-1. Immunol Today 1994;15:475-8.
22. Nara PL, Garrity R. Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Vaccine 1998;16:1780-7.